ANN ARBOR, Mich., July 27 Adeona Pharmaceuticals, Inc., (Amex: AEN), announced today that Julie A. Caudill, B.B.A., has been appointed Vice President of Finance and Corporate Controller. Ms. Caudill brings to Adeona more than 15 years of biotechnology-related accounting and Securities and Exchange Commission compliance experience.
For the past 15 years, Ms. Caudill served in a variety of financial reporting positions at Aastrom Biosciences, Inc., a publicly-traded biotech company developing autologous cellular therapies. Her most recent position at Aastrom was Corporate Controller and Corporate Secretary. She has experience in financial reporting, internal and external audit management, budget planning and control, treasury operations, and stock option reporting. Prior to Aastrom, Ms. Caudill served as Accounting Manager at KMS Industries, Inc., and Senior Accountant at Gelman Sciences, Inc. She earned her Bachelor of Business Administration from Eastern Michigan University.
"We are excited to have attracted a financial person of Julie's experience, integrity and character to our company," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "Given our multiple clinical trials underway and a growing clinical reference laboratory business, it was critical for us to strengthen our internal financial reporting expertise with a high caliber individual like Julie."
About Adeona Pharmaceuticals, Inc.
Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration. Further information on the company is available at www.adeonapharma.com
This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our growing clinical reference laboratory business. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of our clinical trials to achieve desired results, a failure of our clinical reference laboratory to continue to grow or a failure to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.